What the term means
People searching for johnson and johnson orthopedic implants are usually looking for products associated with DePuy Synthes, the orthopaedics business historically reported within Johnson & Johnson MedTech. The portfolio is broad. It includes hip and knee replacement systems, shoulder products, trauma plates and screws, intramedullary nails, spine implants, sports medicine devices, biomaterials, instruments, and digital surgery tools used to support implant procedures.
The most important recent update is corporate rather than surgical. On October 14, 2025, Johnson & Johnson announced its intent to separate its Orthopaedics business into a standalone company operating as DePuy Synthes. In its Form 10-Q for the quarter ended June 28, 2026, Johnson & Johnson said it was still exploring separation paths, with a targeted 18-to-24-month timeline after the announcement. This article explains what the brand covers, what has changed recently, and how patients and care teams can evaluate implant choices without treating a brand name as the only decision factor.
For broader implant category coverage, see our Implants section.
How DePuy Synthes fits within Johnson & Johnson
Johnson & Johnson’s medical technology business has included orthopaedics alongside surgery, cardiovascular, and vision products. Within orthopaedics, DePuy Synthes is the name most closely tied to joint reconstruction, trauma, extremities, spine, sports medicine, craniomaxillofacial products, and related enabling technologies.
The naming can be confusing in hospital records and product documents. Depending on the source, a device may be described as DePuy, Synthes, DePuy Synthes, Johnson & Johnson MedTech, or Johnson & Johnson. In practical terms, a patient’s implant card, hospital invoice, surgeon’s operative note, or device label may show a DePuy Synthes product name even when the broader corporate source is Johnson & Johnson.
The planned separation adds another layer. Johnson & Johnson’s October 2025 announcement said the standalone DePuy Synthes business would address a global orthopaedics market opportunity of more than $50 billion and serve about seven million patients annually. The same announcement cited approximately $9.2 billion in 2024 orthopaedics sales. Johnson & Johnson’s 2025 annual report later reported $9.3 billion in 2025 Orthopaedics franchise sales, up 1.1% from 2024. Because the transaction is subject to approvals, consultations, market conditions, and final corporate decisions, it should be treated as a planned separation rather than a completed fact.
Main types of Johnson & Johnson orthopedic implants
Johnson & Johnson orthopedic implants are not one device or one material. They are a family of systems designed for different anatomical problems and surgical procedures. A hip stem, a knee tibial base, a shoulder replacement component, a spinal cage, and a fracture plate all fall under the broad orthopaedic device umbrella, but they serve very different clinical purposes.
| Area | What it generally includes | Examples and decision factors |
|---|---|---|
| Hip reconstruction | Femoral stems, acetabular cups, liners, heads, and revision options for total hip arthroplasty. | Publicly listed DePuy Synthes examples include ACTIS Total Hip Solutions and ceramic head options. Surgeons consider anatomy, bone quality, bearing surface, fixation method, and revision risk. |
| Knee reconstruction | Total knee, cementless knee, rotating platform, medial stabilized, and revision systems. | The ATTUNE portfolio is a major DePuy Synthes knee platform. Choice depends on ligament condition, alignment, fixation, surgeon experience, and whether the case is primary or revision surgery. |
| Shoulder and extremities | Shoulder replacement systems and implants for upper and lower extremity reconstruction. | Recent company materials have highlighted shoulder innovation. These systems are selected based on soft tissue status, bone loss, arthritis pattern, and functional goals. |
| Trauma | Plates, screws, nails, external fixation, and systems for fracture stabilization. | Examples include variable-angle locking plates, clavicle plates, wrist treatment systems, and advanced nailing systems. Trauma decisions depend on fracture pattern, bone quality, and timing of mobilization. |
| Spine | Interbody spacers, plates, rods, screws, cages, and supporting instruments. | Listed examples include ACIS anterior cervical interbody products and ANTEGRA plate systems. Surgeons evaluate spinal level, instability, deformity, neurological risk, and fusion strategy. |
| Sports medicine and biomaterials | Soft tissue fixation, anchors, graft-related products, and materials used with orthopaedic repair. | These are often used in ligament, tendon, cartilage, and arthroscopic procedures rather than joint replacement alone. |
The table is not a recommendation to request a specific brand. It is a framework for understanding what may be meant when a surgeon, hospital, or device record refers to a Johnson & Johnson or DePuy Synthes implant.
What changed recently in the orthopaedics business
The most visible change is the planned separation of DePuy Synthes. Johnson & Johnson said the move is intended to allow the orthopaedics business to operate with a more focused business model while Johnson & Johnson concentrates investment on selected higher-growth areas in innovative medicine and medtech. The company’s disclosed target window is 18 to 24 months after October 14, 2025, pointing roughly to April through October 2027. Its filings also state that there is no assurance on final timing or completion.
Recent financial data show that orthopaedics remains a material part of Johnson & Johnson MedTech. In the fiscal second quarter ended June 28, 2026, Johnson & Johnson reported Orthopaedics sales of $2.418 billion, up 4.9% as reported and 4.2% operationally from the prior-year quarter. The same filing reported $441 million in hips, $410 million in knees, $827 million in trauma, and $740 million in spine, sports, and other orthopaedics for the quarter. For the first six months of 2026, Orthopaedics sales were $4.801 billion.
Product development is also moving beyond the implant alone. On June 9, 2026, DePuy Synthes announced U.S. commercial availability of VELYS Hip Navigation with AI Assistance for total hip arthroplasty. That technology is not itself a hip implant. It is a navigation and software solution intended to support intraoperative decision-making around measurements such as leg length, offset, and cup position. Johnson & Johnson’s Q2 2026 filing also connected knee growth partly to the ATTUNE portfolio and pull-through related to VELYS robotic-assisted solutions. For care teams and purchasing groups, this means implant decisions may increasingly sit within a broader procedure ecosystem that includes instruments, planning tools, navigation, robotics, and service support.
Safety, recalls, and regulatory context
Orthopaedic implants are regulated medical devices, and no implant system removes the risks of surgery. The U.S. Food and Drug Administration describes implant-related risks broadly as including surgical risks during placement or removal, infection, and implant failure. In joint replacement, other known concerns can include loosening, wear, instability, dislocation, fracture, adverse tissue reaction, and the possibility of revision surgery.
Recalls should be read carefully. An FDA medical device recall may involve a correction, removal, labeling update, field safety notice, or other action. It does not automatically mean every patient with that manufacturer’s implant needs surgery, and it does not mean all products in a portfolio are affected. The recall notice must be matched to the exact product name, item number, lot number, date, and clinical situation.
DePuy Synthes has had both historical and recent recall listings in FDA records. Recent examples in 2026 include Class II recall entries involving certain ATTUNE Revision Hinge Knee components. Class II generally indicates that use of or exposure to the product may cause temporary or medically reversible adverse health consequences, or that the probability of serious adverse consequences is remote. That classification is important because it is different from a Class I recall, the FDA’s highest-risk category. See also: Fixation.
The best-known historical issue is the DePuy ASR hip recall. In August 2010, DePuy Orthopaedics issued a voluntary worldwide recall of the ASR XL Acetabular System and DePuy ASR Hip Resurfacing System after higher-than-expected revision rates were reported. Johnson & Johnson’s 2025 annual report stated that the ASR settlement program had resolved more than 10,000 U.S. claims, while a small number of lawsuits remained active in several countries. The same annual report also listed pending claims related to the PINNACLE Acetabular Cup System. These histories are relevant background, but they should not be generalized to every DePuy Synthes product currently used in orthopaedic care.
How surgeons and hospitals evaluate implant systems
Implant choice is usually a clinical decision made by the orthopaedic surgeon within the hospital’s approved device options. Patients can and should ask questions, but most surgeons do not treat implant selection like a consumer product menu. The American Academy of Orthopaedic Surgeons has stated in patient education materials that many manufacturers market implants and surgeons may have preferences, but there is no strong evidence that one knee implant brand or design is superior to all others in function or longevity for every patient.
That does not mean the brand is irrelevant. It means outcomes depend on a combination of factors: diagnosis, bone quality, deformity, body weight, age, activity level, allergy history, surgical approach, component sizing, alignment, fixation, infection prevention, rehabilitation, and surgeon experience with the chosen system. A well-established implant used by a high-volume surgeon who understands its instrumentation may be more appropriate than a newer design selected only because it appears innovative.
Hospitals and purchasing teams evaluate implant systems through a different lens. They compare clinical evidence, registry data, FDA clearance or approval status, recall history, inventory needs, instrument trays, training requirements, supply continuity, contract terms, and compatibility with navigation or robotic platforms. For DePuy Synthes specifically, the planned corporate separation may also raise questions about future contracting, service support, and product continuity, although it does not by itself change the clinical status of an already implanted device.
Questions to ask before a procedure
Patients do not need to become device engineers, but a focused conversation can reduce confusion and help document the decision. Useful questions include:
- What is the exact implant system you plan to use, and why is it appropriate for my anatomy and diagnosis?
- How long has this implant or platform been in clinical use?
- How many procedures have you performed with this system?
- Is the case primary surgery, revision surgery, trauma fixation, or another category?
- What materials will be implanted, such as titanium alloy, cobalt-chromium, ceramic, polyethylene, or bone cement?
- Are there any metal allergy, infection risk, bone quality, or activity-level issues that change the implant choice?
- Will navigation, robotic assistance, or patient-specific planning be used, and does it affect implant positioning?
- How will I receive an implant card or record with model and lot details?
- What symptoms should prompt follow-up after surgery?
- If a future recall or safety notice affects my device, how will the hospital or surgeon contact me?
Hospitals and care teams may add procurement questions: whether the system has adequate inventory depth for unusual sizes, whether revision components are available, whether instruments can be sterilized efficiently, and whether manufacturer support is consistent across sites.
Frequently asked questions
Are Johnson and Johnson orthopedic implants the same as DePuy Synthes implants?
In most orthopaedic contexts, yes. The implants people describe as Johnson & Johnson orthopedic implants are usually DePuy Synthes products within the Johnson & Johnson MedTech orthopaedics business. Device records may use either the corporate name or the specific DePuy Synthes product name.
Will the planned DePuy Synthes separation affect patients who already have an implant?
The corporate separation, by itself, does not change the implanted device inside a patient. Follow-up care should remain based on the patient’s symptoms, operative records, device details, and surgeon guidance. Administrative items such as branding, contracting, customer service, or product documentation may evolve if the separation is completed.
Are DePuy Synthes hip or knee implants recalled?
Some specific DePuy Synthes products and lots have been subject to recalls, including historical ASR hip systems and certain more recent knee-related components. A recall must be matched to the exact product and lot information. It is not accurate to say that all DePuy Synthes hip or knee implants are recalled.
Can a patient choose a different implant brand?
Patients can ask about alternatives, but surgeons typically choose implants based on clinical need, hospital availability, training, instrumentation, and their own experience with the system. If a patient has concerns about a specific device, the best step is to discuss them before surgery and ask for the rationale in plain language.
What should I do if I already have a DePuy Synthes implant and develop pain?
Contact the surgeon or orthopaedic practice that performed the procedure, especially if pain is new, worsening, associated with swelling, instability, fever, drainage, or reduced function. Bring the implant card or operative report if available. Pain does not automatically mean implant failure, but it should be evaluated clinically.